913718-34-0 Usage
Uses
Used in Medicinal Chemistry Research:
(4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one is utilized as a research compound for exploring its pharmacological properties and potential applications in the development of new drugs. Its specific biological activity and molecular targets within the body need to be further investigated to understand its full potential.
Used in Drug Development:
In the pharmaceutical industry, (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one serves as a lead compound for the design and synthesis of novel therapeutic agents. Its complex molecular structure and potential interactions with biological targets make it a valuable candidate for creating new medications to treat various diseases and conditions.
Additional research and studies are essential to fully comprehend the potential uses and implications of (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one in different applications. As our understanding of its properties and interactions grows, so too will the range of possible applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 913718-34-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,7,1 and 8 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 913718-34:
(8*9)+(7*1)+(6*3)+(5*7)+(4*1)+(3*8)+(2*3)+(1*4)=170
170 % 10 = 0
So 913718-34-0 is a valid CAS Registry Number.
913718-34-0Relevant academic research and scientific papers
Catalytic enantioselective Steglich rearrangements using chiral N-heterocyclic carbenes
Campbell, Craig D.,Concellon, Carmen,Smith, Andrew D.
experimental part, p. 797 - 811 (2011/08/06)
The evaluation of a range of enantiomerically pure NHCs, prepared in situ from imidazolinium or triazolium salt precatalysts, to promote the catalytic enantioselective Steglich rearrangement of oxazolyl carbonates to their C-carboxyazlactones, is reported. Modest levels of enantioselectivity (up to 66% ee) are observed using oxazolidinone derived NHCs.
FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS
-
Page/Page column 52, (2008/06/13)
A series of 5,6-dihydro-l,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of b.enefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
